| Literature DB >> 28122540 |
Linlin Wang1,2, Dabei Liu1,2, Jibin Lu2, Suning Zhang2, Xueying Yang3.
Abstract
BACKGROUND: Ongoing improvements in technique and instruments for video-assisted thoracoscopic surgery (VATS) have made minimally-invasive uniportal VATS lobectomy a reality. However, the outcomes of the procedure are still under investigation, and at present, uniportal VATS lobectomy is performed infrequently at most hospitals. We have therefore reviewed our outcomes with this procedure in an attempt to validate its safety, efficacy, and feasibility.Entities:
Keywords: Lobectomy; Minimally invasive surgery; Uniportal; VATS
Mesh:
Year: 2017 PMID: 28122540 PMCID: PMC5264479 DOI: 10.1186/s12885-017-3069-z
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Uniportal video assisted thoracoscopic surgery (VATS) lobectomy. A single incision of approximately 4.0 cm is made in the 4th or 5th intercostal space at the anterior axillary line. a A specially-designed wound protector is inserted, forming two channels, one for the thoracoscope and the other for the surgical instruments. b Left pneumonectomy. c A U-shaped suture is placed around the chest tube in order to close the incision immediately after removal of the tube. d One month after right upper lobectomy
Baseline patient characteristics
| Characteristic | Uniportal VATS ( | Two-port VATS ( | Three-port VATS ( |
|
|---|---|---|---|---|
| Age (Mean ± SD) | 57.12 ± 6.43 | 54.36 ± 7.6 | 61.32 ± 7.54 | <0.001 |
| Sex (%) | 0.288 | |||
| Male | 31 (42.47%) | 45 (52.33%) | 53 (54.08%) | |
| Female | 42 (51.53%) | 41 (47.67%) | 45 (45.92%) | |
| Pulmonary function (Mean ± SD) | ||||
| FVC (% predicted) | 90.83 ± 13.43 | 88.32 ± 15.87 | 85.33 ± 15.87 | 0.064 |
| FEV1 (% predicted) | 86.18 ± 12.91 | 82.70 ± 16.30 | 80.71 ± 19.08 | 0.104 |
| MVV (% predicted) | 69.26 ± 18.84 | 67.75 ± 25.10 | 70.78 ± 21.43 | 0.649 |
| Arterial blood gas analysis (Mean ± SD) | ||||
| PAO2 (mmHg) | 84.87 ± 12.62 | 83.10 ± 18.43 | 79.75 ± 14.20 | 0.085 |
| PACO2 (mmHg) | 41.26 ± 5.01 | 42.37 ± 5.85 | 42.61 ± 6.12 | 0.286 |
| SAO2 (%) | 96.55 ± 1.42 | 95.58 ± 2.47 | 95.72 ± 3.37 | 0.048 |
| Lobectomy (%) | ||||
| Right upper | 16 (21.92%) | 28 (32.56%) | 23 (23.47%) | 0.237 |
| Right middle | 4 (5.48%) | 6 (6.98%) | 11 (11.22%) | 0.352 |
| Right lower | 18 (24.66%) | 13 (15.12%) | 23 (23.47%) | 0.254 |
| Right middle and lower | 3 (4.11%) | 1 (1.16%) | 0 (%) | 0.069 |
| Left upper | 12 (16.44%) | 16 (18.6%) | 24 (24.49%) | 0.388 |
| Left lower | 19 (26.03%) | 22 (25.58%) | 16 (16.33%) | 0.207 |
| Left pneumonectomy | 1 (1.37%) | 0 (%) | 1 (1.02%) | 0.744 |
FVC forced vital capacity, FEV1 forced expiratory volume in 1 second, MVV maximal ventilatory volume, PAO 2 partial pressure of oxygen in artery, PACO 2 partial pressure of carbon dioxide in artery, SAO 2 arterial oxygen saturation
Pathology results
| Pathological types | Uniportal VATS (%) ( | Two-port VATS (%) ( | Three-port VATS (%) ( |
|
|---|---|---|---|---|
| Primary lung cancer | 51 (69.86%) | 56 (65.12%) | 71 (72.45%) | 0.556 |
| Adenocarcinoma | 34 (46.58%) | 38 (44.19%) | 52 (53.06%) | 0.459 |
| Squamous cell carcinoma | 16 (21.92%) | 15 (17.44%) | 13 (13.27%) | 0.330 |
| Adenosquamous | 0 (0%) | 1 (1.16%) | 1 (1.02%) | 1.000 |
| Large cell carcinoma | 1 (1.37%) | 0 (0%) | 2 (2.04%) | 0.506 |
| Carcinoid tumors | 0 (0%) | 1 (1.16%) | 0 (0%) | 0.619 |
| Carcinosarcoma | 0 (0%) | 0 (0%) | 1 (1.02%) | 1.000 |
| Small cell carcinoma | 0 (0%) | 1 (1.16%) | 2 (2.04%) | 0.780 |
| Benign disease | 22 (30.14%) | 30 (34.88%) | 27 (27.55%) | 0.556 |
| Inflammation | 3 (4.11%) | 6 (6.98%) | 7 (7.14%) | 0.676 |
| Pulmonary cyst | 4 (5.48%) | 4 (4.65%) | 4 (4.08%) | 0.933 |
| Tuberculosis | 4 (5.48%) | 9 (10.47%) | 7 (7.14%) | 0.482 |
| Pulmonary hamartoma | 2 (2.74%) | 3 (3.49%) | 3 (3.06%) | 1.000 |
| Pulmonary fibrosis | 4 (5.48%) | 3 (3.49%) | 1 (1.02%) | 0.223 |
| Bronchiectasis | 5 (6.85%) | 4 (4.65%) | 4 (4.08%) | 0.723 |
| Lung sequestration | 0 (0%) | 0 (0%) | 1 (1.02%) | 1.000 |
| Spindle cell lipoma | 0 (0%) | 1 (1.16%) | 0 (0%) | 0.619 |
There were no significant difference in these results among the three groups (all P > 0.05)
Distribution of primary lung cancers by pathologic stage
| Stage | Uniportal VATS (%) ( | Two-port VATS (%) ( | Three-port VATS (%) ( |
|
|---|---|---|---|---|
| Stage I | 27 (52.94%) | 29 (51.79%) | 34 (47.89%) | 0.839 |
| IA | 13 (25.49%) | 13 (23.21%) | 19 (26.76%) | 0.900 |
| IB | 14 (27.45%) | 16 (28.57%) | 15 (21.13%) | 0.578 |
| Stage II | 21 (41.18%) | 24 (42.86%) | 30 (42.25%) | 0.984 |
| IIA | 11 (21.57%) | 14 (25.00%) | 14 (19.72%) | 0.773 |
| IIB | 10 (19.61%) | 10 (17.86%) | 16 (22.54%) | 0.802 |
| Stage III or greater | 3 (5.88%) | 3 (5.36%) | 7 (9.86%) | 0.625 |
| IIIA | 3 (5.88%) | 3 (5.36%) | 5 (7.04%) | 0.928 |
| IIIB | 0 (0%) | 0 (0%) | 1 (1.41%) | 1.000 |
| IVa | 0 (0%) | 0 (0%) | 1 (1.41%) | 1.000 |
a Isolated brain metastasis following metastasectomy prior to being evaluated for lobectomy
There were no significant difference in these results among the three groups (all P > 0.05)
Surgical results (Mean ± SD)
| Characteristic | Uniportal VATS ( | Two-port VATS ( | Three-port VATS ( |
|
|---|---|---|---|---|
| Operative time (min) | 154.88 ± 31.31 | 163.91 ± 49.72 | 162.84 ± 68.18 | 0.519 |
| Blood loss (mL) | 92.5 ± 22.66 | 100 ± 33.89 | 103.21 ± 27.41 | 0.051 |
| Drainage time (days) | 4.55 ± 1.41 | 5.34 ± 1.81 | 5.26 ± 3.15 | 0.069 |
| Length of hospital stay (days) | 8.63 ± 2.06 | 8.95 ± 2.40 | 9.55 ± 3.18 | 0.069 |
| Number of lymph nodes retrieved (lung cancer patients only) | 13.56 ± 3.79 | 12.68 ± 3.17 | 12.71 ± 4.18 | 0.252 |
| Number of nodal stations explored (lung cancer patients only) | 7.05 ± 1.15 | 6.73 ± 1.28 | 6.56 ± 1.49 | 0.059 |
There were no significant difference in these results among the three groups (all P > 0.05)
Postoperative complications
| Complication | Uniportal VATS (%) ( | Two-port VATS (%) ( | Three-port VATS (%) ( |
|
|---|---|---|---|---|
| Pneumonia | 2 (2.74%) | 3 (3.49%) | 3 (3.06%) | 1.000 |
| Prolonged air leak | 1 (1.37%) | 2 (2.33%) | 3 (3.06%) | 0.879 |
| Cardiac arrhythmias | 1 (1.37%) | 2 (2.33%) | 1 (1.02%) | 0.832 |
| Hemothorax | 0 (0%) | 1 (1.16%) | 2 (2.04%) | 0.780 |
| Respiratory failure | 0 (0%) | 1 (1.16%) | 0 (0%) | 0.619 |
| Totals | 4 (5.48%) | 9 (10.47%) | 9 (9.18%) | 0.514 |
The overall rate of postoperative complications was no significantly differences (all P > 0.05) in the uniportal VATS group compared to the two- and three-port VATS groups
Fig. 2Visual analog scale (VAS) pain scores. The postoperative pain scores in the uniportal VATS group after surgery were significantly lower compared to those of the two-port and three-port VATS groups (P < 0.05)